subject: Vision Shopsters: Neurodegenerative Market Forecast To 2013 [print this page] Which Alzheimer's blockbuster faces diminishing sales within the next decade? What has the potential to take its place? Which class of MS drugs is emerging as successful? What innovative treatments are on the horizon? Who is on track to become a market leader? Neurodegenerative Market Forecast to 2013 answers these questions - and much more - so you can navigate the still-uncharted market landscape with ease. This overview is comprehensive, covering only the most relevant information on Alzheimer's, MS and Parkinson's.....all in one place. With in-depth brand and drug class analyses, make research and spending decisions with the utmost confidence. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, and whole drug classes. Find all you need to tap into or maximize your presence in this lucrative space.
Table Of Contents :
Alzheimers, Amyloid Beta Therapies, Bapineuzumab / AAB-001, LY450139, LY2062430, ACC-001, Acetylcholinesterase Inhibitors, Aricept, Excelon, Razadyne, NMDA Antagonists, Namenda: also known as Ebixa in some EU countries, Ebixa: also known as Namenda in US, Other Alzheimers Therapies Targeting Neurotransmitters, Abilify, Dimebon, AZD3480 / TC-1734, SB 742457, Other Alzheimers Therapies, MEM1003, Tanakan, Avandia XR, Multiple Sclerosis (MS), Immunomodulators, Copaxone, Fingolimod (FTY720), BG-12 (Phase III), Laquinimod (Phase III), Teriflunomide, Oral Leustatin, Interferon Beta, Avonex, Rebif, Betaferon / Betaseron, Monoclonal antibodies, Rituxan, HuMax CD, Campath, Tysabri, SB683699, Other MS Therapies, Dirucotide (MBP8298), Fampridine SR, Parkinsons, Dopamineric drugs, Apokyn, Mirapex, Sinemet, Requip XL, Comtan / Stavelo, Other Drugs, Agilect / Azilect, ACP-103, Droxidopa
For more information on the report, kindly visit :
